The treatment of hepatitis C virus (HCV) has made significant advances with the development of new direct-acting antivirals. Nucleotide polymerase inhibitors are one class of these new medications that have been shown to be highly effective, safe and well tolerated as part of an antiviral regimen. Sofosbuvir has become the first drug in this class to be approved for clinical use, supported by results from extensive phase II and phase III clinical trials. This review will further discuss nucleotide polymerase inhibitors, including the data supporting their use as part of interferon-free HCV treatment regimens.
Keywords: Hepatitis C; Nucleoside/nucleotide polymerase inhibitors; Sofosbuvir.
Copyright © 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.